


SAVE THE DATE

# The Fourth Transatlantic Exchange in Oncology: Radiopharmaceutical Therapy Meets Oncology



WEDNESDAY, 19 MARCH, 2025 | 10:00 AM CET | HYBRID

## OVERVIEW

With novel radiopharmaceutical therapies entering clinical trials and into clinical practice, the 2025 Transatlantic Exchange in Oncology will focus on bringing together key experts from Boston, USA and Paris, France to highlight the latest advances in the application of these targeted agents for oncology. The 1-day event will deliver a comprehensive overview of this highly competitive and dynamic area within the R&D landscape, enabling attendees to understand cutting-edge research as well as the challenges in bringing these therapies to routine clinical application.

## AGENDA

10:00–10:20

### Opening and Welcome

Toni K. Choueiri, MD, Karim Fizazi, MD, PhD, Kevin Haigis, PhD, Fabrice Barlesi, MD, PhD, Patrick Therasse, MD, PhD

10:20–11:50

### SESSION 1: Precision Oncology & Molecular Imaging: Early Detection and Characterization

Moderators: Fabrice Barlesi, MD, PhD, Toni K. Choueiri, MD

*Session includes a 15-min Q&A and 15-min Break*

#### Antibody-Based Radiotheranostics for Tumor Characterization and Therapy

Speaker: Fay Nicolson, PhD

#### Advances in Genitourinary Cancers (Lessons Learned From PSMA)

Speaker: Ronan Flippot, MD

#### The Model of Breast Cancer: From In Vivo Target to Diagnostic Radiopharmaceutical

Speaker: Théophraste Henry, PhD

#### Using Imaging to Test Tumor Biology and Heterogeneity

Speaker: Himisha Beltran, MD

11:50–12:30

### Keynote Address

Moderators: Fabrice André, MD, PhD, Heather Jacene, MD

*Session includes a 10-min Q&A*

#### Seeing Beyond VISION: Designing RLT Trials That Yield a Survival Benefit

Speaker: Michael J. Morris, MD, FASCO

12:30–14:30

### SESSION 2: How to Go From Non-Radiolabeled Target to a Radiolabeled Active Product

Moderators: Toni K. Choueiri, MD, Patrick Therasse, MD, PhD

*Session includes a 15-min Q&A and 15-min break*

#### Are My Target and Probe Suitable for Radiolabeling?

Speaker: Mohammad Rashidian, PhD

#### Developing Targeted Alpha Therapeutics: Heartbreak of Happily Ever After?

Speaker: Anthony P. Belanger, PhD

#### The Radiolabeled ADC: The Pharmaceutical Challenges

Speaker: Angelo Paci, PharmD, PhD

#### The First in Human: How to Deal With Phase I Studies

Speaker: Christophe Massard, MD, PhD

14:30–16:15

### SESSION 3: Future Directions and Latest Clinical Applications

Moderators: Karim Fizazi, MD, PhD, Heather Jacene, MD

*Session includes a 15-min Q&A and 15-min break*

#### Monitoring and Tumor Assessment Post-Radioligand Therapy

Speaker: Praful Ravi, MB, BChir, MRCP

#### Strategies to Target the Immune system with Radiolabelled Antibodies

Speaker: Bertrand Kuhnast, MD

#### The Impact of Molecular Profile on Response to Treatment: The UNLOCK Program

Speaker: Yohann Loriot, MD, PhD

#### Radiopharmaceuticals in Heme Malignancies: Waldenström Macroglobulinemia

Speaker: Jorge J. Castillo, MD

#### Radioconjugates Using Small Linear Peptides

Speaker: Kevin Lee, PhD, MBA

16:15–17:15

### SESSION 4: Radioligand Therapies: Academia and Industry Perspectives

Moderators: Désirée Deandreis, MD, Leonhard Schaez, MD

*Session includes a 15-min Q&A and 15-min break*

#### Clinical Development of AlphaMedix

Speaker: Amal Saidi, PhD

#### Challenges in Scaling Up Facilities

Speaker: Désirée Deandreis, MD

#### Challenges in Scaling Up Production

Speaker: Val Nassiri, PharmD, MBA

17:15–17:30

### Closing Remarks

Chairs to close: Toni K. Choueiri, MD, Karim Fizazi, MD, PhD

Registration will open in January 2025